U.S. Markets closed

Celsion Corporation (CLSN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.85-0.07 (-3.65%)
At close: 4:00PM EDT
People also watch
  • Seems like the only way to make a little money on this pos it to short it.
  • Premarket is up 6 cents on no new data? What is the catalyst?.
  • When they make the June earnings announcement it should show that they have reached a new milestone. $250,000,000 in accumulated losses. That's 1/4 of a billion dollars squandered not to mention the years that an effective cancer treatment could have been approved and in use saving/prolonging lives. Good job management!
  • Based on what I just read I don't see any products ready for market. They have a phase 3, phase 2 and a phase 1 clinical trial product in the works. I see years before they get to market. I bought recently but I bought too soon. The company looks optimistic and promising but I can't wait that long. I hope to break even and turn the risk over to those with time on their hands.
  • Friday after close filing shows a Director buying 13000 shs. in the open market on Friday at av. cost of 1.89...Hmmmmm.
  • "The estimated net proceeds to the Company from the sale of the shares of common stock or pre-funded warrants in the registered direct offering are expected to be approximately $4.3 million. The Company intends to use the net proceeds for general corporate purposes."

    clsn nets only $4.3 of $5.0 million - commissions/costs $700,000, or 14%
    aside from shorts, who is the winner on these constant fundraisers that are followed by repeated reverse splits?
  • The DMC last looked at the OPTIMA data Nov. 2016 and unanimously recommended continuation. Let's say they take another peek in mid 2018 and data is tracking the same percentages as the HEAT data.
    Since safety is not a concern, do you think the trial will be halted on overwhelming benefit?


    Celsion Announces Data Monitoring Committee Unanimously Recommends Continuation Of Phase III OPTIMA Study Of ThermoDox® For Primary Liver Cancer
  • CLSN is a certified pump and dump stock. Always short it when it spikes and buy the dip. Next dip is $1.40.
  • Just hoping to break even.
  • until the day they are sufficiently capitalized with 2 years of working capital
    this will continue going below $1

    rather than continuing dilute over n over, time for management to sellout

    just saying
  • Today is Huge for Celsion Corp (CLSN)...this is a stable and growing company with great financials and now superb study news = $$$ for the company. Soon the Big Name Hedge funds will start buying in now as this stock is definitely on the radar now. This stock should continue to trend up as the day goes on and even more once the upgrades start and the 1yr target increases Big Time...Baker Brothers Advisors, RA Capital and Broadfin Capital, etc. Great fundamentals, management and guidance that's in favor of share holders plus larger companies that my want to buyout Celsion.
  • $CLSN:
    Any News On INSIDER Trading???... I just read that one exec' bought 100,000 on Friday... If True, this means it could be A GOOD-TIME To BUY!!!... BULLISH!!
  • Next buying opportunity at 1.00 dollar lol
  • CLSN is financially messed up and worth just $7.5M now. It's just crazy! I wonder if management has something to do with insider trading of this pump and dump cycle since January.
  • This stock is a buy and hold
  • I see this investment shooting Up again as well. I saw the same exact scenario with PULM.
  • GEN-1 Offers Hope to Ovarian Cancer
    A meeting with management revealed new information on the
    IL-12 gene therapy.
    Our meeting with Celsion’s execs yesterday
    gave us an opportunity to discuss the data presented at the ASCO
    meeting earlier this month. In sum, the results point to two roles
    for GEN-1 in the 1st line ovarian cancer setting.
    The Ovation Study treated patients with advanced ovarian
    cancer who were scheduled to receive standard neoadjuvant
    The patients also received one of four doses of
    GEN-1 to determine a maximum tolerated dose or recommended
    dose for future studies. The neoadjuvant setting provided the
    Company with tissue samples prior to (biopsy) and after treatment
    (surgical resection) to assess the effect of the therapy via
    translational analyses (i.e., impact on cytokine levels and the
    tumor microenvironment).
    Translational data revealed the stimulatory effect of GEN-1
    on the immune system.
    A dose-response relationship was
    observed between the therapy and levels of IL-12 and the
    downstream cytokine interferon-
    in the peritoneal fluid, while
    pathological levels of TNF-
    were reduced. Plasma levels
    of the four compounds changed modestly, suggesting that
    GEN-1 had little systemic effect. That finding is consistent
    with a benign safety profile of the therapy. In addition,
    the GEN-1 neoadjuvant treatment reduced the presence of
    immunosuppressive biomarkers in the malignant tissue and
    increased the density of cytotoxic (CD8+) T cells in the tumors.
    GEN-1 appears to extend patient survival.
    The data is still
    maturing, but only one of the 14 patients enrolled has exhibited
    disease progression and most have reached the 11-month mark
    since being treated. This suggests GEN-1 extends PFS beyond
    the 12 months achieved with neoadjuvant chemotherapy alone.
    And it is consistent with the 100% control rate reported for the
    14 subjects and R0 (potentially curative) resection achieved in
    nine patients. An extended PFS may convince the FDA to grant
    “breakthrough” status to GEN-1.
    A GEN-1 pivotal trial will likely commence in early 2018 to test
    the therapy in the 1st-line setting
    . While the study’s design is
    not yet complete, we believe Celsion will seek U.S., European,
    and possibly Japanese authorization to test its IL-12 gene therapy
    for ovarian cancer in the standard neoadjuvant regimen and as
    an adjuvant therapy following surgery. Thus, GEN-1 may become
    the standard of care for a malignancy that has evaded modern
    medicine for 40 years.
    We are maintaining our BUY rating with a $9.00 price target
  • Another reverse split. I missed this one. After having 10,000 shares, I now have about 15. I wonder if their is or ever will be a viable therapy from CELSION. After 15 years and alot of sucker's money, I don't know how they could raise any more money. If there is indeed something noteworthy in all their research, it needs to be sold to one of the pharmacy big boys to finish developing. CELSION appears to be more of a make work project for a few individuals.
  • So i recently came across a company called "CYTX" (symbol) who have a product that is a liposomal encapsulation of doxorubicin....clsn has no patent......
  • These guys can't make a decision and stick with it. Cancel offering, make offering, cancel offering, what's next?